Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.

Maitre E, Bertrand P, Maingonnat C, Viailly PJ, Wiber M, Naguib D, Salaün V, Cornet E, Damaj G, Sola B, Jardin F, Troussard X.

Oncotarget. 2018 Jun 22;9(48):28866-28876. doi: 10.18632/oncotarget.25601. eCollection 2018 Jun 22.

2.

HSP110 sustains chronic NF-κB signaling in activated B cell diffuse large B cell lymphoma through MyD88 stabilization.

Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, Pangault C, Fest T, Ramla S, Jardin F, Wolz OO, Weber ANR, Garrido C, Jego G.

Blood. 2018 Jun 5. pii: blood-2017-12-819706. doi: 10.1182/blood-2017-12-819706. [Epub ahead of print]

PMID:
29871863
3.

Correction to: Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Decazes P, Becker S, Toledano MN, Vera P, Desbordes P, Jardin F, Tilly H, Gardin I.

Eur J Nucl Med Mol Imaging. 2018 May 26. doi: 10.1007/s00259-018-4053-9. [Epub ahead of print]

PMID:
29802427
4.

Novel molecular classifications of DLBCL.

Dubois S, Jardin F.

Nat Rev Clin Oncol. 2018 Aug;15(8):474-476. doi: 10.1038/s41571-018-0041-z. No abstract available.

PMID:
29789700
5.

Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Decazes P, Becker S, Toledano MN, Vera P, Desbordes P, Jardin F, Tilly H, Gardin I.

Eur J Nucl Med Mol Imaging. 2018 Apr 28. doi: 10.1007/s00259-018-4041-0. [Epub ahead of print] Erratum in: Eur J Nucl Med Mol Imaging. 2018 May 26;:.

PMID:
29705879
6.

STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.

Miloudi H, Leroy K, Jardin F, Sola B.

Cell Signal. 2018 Jun;46:76-82. doi: 10.1016/j.cellsig.2018.02.016. Epub 2018 Mar 1.

PMID:
29501729
7.

Authors' Reply.

Bobée V, Ruminy P, Marchand V, Viailly PJ, Abdel Sater A, Veresezan L, Drieux F, Bérard C, Bohers E, Mareschal S, Dubois S, Jais JP, Leroy K, Figeac M, Picquenot JM, Molina TJ, Salles G, Haioun C, Tilly H, Jardin F.

J Mol Diagn. 2018 Mar;20(2):266. doi: 10.1016/j.jmoldx.2017.12.001.

PMID:
29482771
8.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G.

Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20. Erratum in: Lancet Oncol. 2018 Jun;19(6):e283.

PMID:
29475724
9.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

10.

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, Jardin F, Tilly H, Becker S.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):680-688. doi: 10.1007/s00259-017-3907-x. Epub 2018 Jan 17.

PMID:
29344718
11.

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.

Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM.

Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.

12.

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.

Lab Invest. 2018 Mar;98(3):371-379. doi: 10.1038/labinvest.2017.124. Epub 2017 Dec 18.

PMID:
29251734
13.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Body S, Esteve-Arenys A, Miloudi H, Recasens-Zorzo C, Tchakarska G, Moros A, Bustany S, Vidal-Crespo A, Rodriguez V, Lavigne R, Com E, Casanova I, Mangues R, Weigert O, Sanjuan-Pla A, Menéndez P, Marcq B, Picquenot JM, Pérez-Galán P, Jardin F, Roué G, Sola B.

Sci Rep. 2017 Oct 24;7(1):13946. doi: 10.1038/s41598-017-14222-1.

14.

Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.

Bobée V, Ruminy P, Marchand V, Viailly PJ, Abdel Sater A, Veresezan L, Drieux F, Bérard C, Bohers E, Mareschal S, Dubois S, Jais JP, Leroy K, Figeac M, Picquenot JM, Molina TJ, Salles G, Haioun C, Tilly H, Jardin F.

J Mol Diagn. 2017 Nov;19(6):892-904. doi: 10.1016/j.jmoldx.2017.07.007. Epub 2017 Oct 17.

PMID:
29054399
15.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group.

N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

16.

A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.

Ben Younes K, Body S, Costé É, Viailly PJ, Miloudi H, Coudre C, Jardin F, Ben Aissa-Fennira F, Sola B.

BMC Cancer. 2017 Aug 10;17(1):538. doi: 10.1186/s12885-017-3530-z.

17.

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours.

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, Perdrix A, Paresy M, Antonietti M, Iwanicki-Caron I, Alhameedi R, Lecleire S, Gangloff A, Schwarz L, Clatot F, Tuech JJ, Frébourg T, Jardin F, Sabourin JC, Sarafan-Vasseur N, Michel P, Di Fiore F.

Br J Cancer. 2017 Sep 26;117(7):1017-1025. doi: 10.1038/bjc.2017.250. Epub 2017 Aug 3.

PMID:
28772284
18.

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.

Jais JP, Molina TJ, Ruminy P, Gentien D, Reyes C, Scott DW, Rimsza LM, Wright G, Gascoyne RD, Staudt LM, Haioun C, Tilly H, Gaulard P, Salles GA, Jardin F, Leroy K.

Haematologica. 2017 Oct;102(10):e404-e406. doi: 10.3324/haematol.2017.166827. Epub 2017 Jul 4. No abstract available.

19.

Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells.

Bouzelfen A, Kora H, Alcantara M, Bertrand P, Latouche JB, Jardin F.

Leuk Res. 2017 Sep;60:53-57. doi: 10.1016/j.leukres.2017.06.006. Epub 2017 Jun 16.

PMID:
28651105
20.

Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.

Fontanilles M, Marguet F, Bohers É, Viailly PJ, Dubois S, Bertrand P, Camus V, Mareschal S, Ruminy P, Maingonnat C, Lepretre S, Veresezan EL, Derrey S, Tilly H, Picquenot JM, Laquerrière A, Jardin F.

Oncotarget. 2017 Jul 18;8(29):48157-48168. doi: 10.18632/oncotarget.18325.

21.

Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report.

Keribin P, Guerrot D, Jardin F, Moizan H.

J Oral Maxillofac Surg. 2017 Dec;75(12):2599-2605. doi: 10.1016/j.joms.2017.05.016. Epub 2017 May 24.

PMID:
28623682
22.

Application of the cghRA framework to the genomic characterization of Diffuse Large B-Cell Lymphoma.

Mareschal S, Ruminy P, Alcantara M, Villenet C, Figeac M, Dubois S, Bertrand P, Bouzelfen A, Viailly PJ, Penther D, Tilly H, Bastard C, Jardin F.

Bioinformatics. 2017 Oct 1;33(19):2977-2985. doi: 10.1093/bioinformatics/btx309.

PMID:
28481978
23.

Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.

Mareschal S, Pham-Ledard A, Viailly PJ, Dubois S, Bertrand P, Maingonnat C, Fontanilles M, Bohers E, Ruminy P, Tournier I, Courville P, Lenormand B, Duval AB, Andrieu E, Verneuil L, Vergier B, Tilly H, Joly P, Frebourg T, Beylot-Barry M, Merlio JP, Jardin F.

J Invest Dermatol. 2017 Sep;137(9):1984-1994. doi: 10.1016/j.jid.2017.04.010. Epub 2017 May 4.

PMID:
28479318
24.

EZH2 alterations in follicular lymphoma: biological and clinical correlations.

Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, Sohier E, Carrère M, Lazarovici J, Casasnovas O, Tonon L, Boyault S, Hayette S, Haioun C, Fabiani B, Viari A, Jardin F, Salles G.

Blood Cancer J. 2017 Apr 21;7(4):e555. doi: 10.1038/bcj.2017.32.

25.

The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.

Camus V, Jardin F, Tilly H.

Expert Rev Mol Diagn. 2017 Jun;17(6):557-566. doi: 10.1080/14737159.2017.1319765. Epub 2017 Apr 27. Review.

PMID:
28415895
26.

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.

Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ.

Ann Oncol. 2017 May 1;28(5):1042-1049. doi: 10.1093/annonc/mdx022.

PMID:
28327893
27.

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.

Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, Salles G, Sujobert P.

Am J Hematol. 2017 Jun;92(6):515-519. doi: 10.1002/ajh.24701. Epub 2017 Mar 24.

28.

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.

Camus V, Miloudi H, Taly A, Sola B, Jardin F.

J Hematol Oncol. 2017 Feb 14;10(1):47. doi: 10.1186/s13045-017-0412-4. Review.

29.

The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.

Sarkozy C, Huet S, Carlton VE, Fabiani B, Delmer A, Jardin F, Delfau-Larue MH, Hacini M, Ribrag V, Guidez S, Faham M, Salles G.

Oncotarget. 2017 Jan 31;8(5):8765-8774. doi: 10.18632/oncotarget.14448.

30.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F.

Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

PMID:
28041583
31.

Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?

Leclerc M, Peffault de Latour R, Michallet M, Blaise D, Chevallier P, Rohrlich PS, Turlure P, Nguyen S, Jardin F, Yakoub-Agha I, Maury S; French Society of Bone Marrow Transplantation and Cell Therapy.

Blood. 2017 Mar 2;129(9):1227-1230. doi: 10.1182/blood-2016-09-726653. Epub 2016 Dec 16. No abstract available.

32.

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.

Clin Cancer Res. 2017 May 1;23(9):2232-2244. doi: 10.1158/1078-0432.CCR-16-1922. Epub 2016 Dec 6.

33.

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.

Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, Sefrioui D, Viailly PJ, Bubenheim M, Moldovan C, Alexandru C, Tennevet I, Rigal O, Guillemet C, Leheurteur M, Gouérant S, Petrau C, Théry JC, Picquenot JM, Veyret C, Frébourg T, Jardin F, Sarafan-Vasseur N, Di Fiore F.

Oncotarget. 2016 Nov 15;7(46):74448-74459. doi: 10.18632/oncotarget.12950.

34.

Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.

Rizzo D, Viailly PJ, Mareschal S, Bohers E, Picquenot JM, Penther D, Dubois S, Marchand V, Bertrand P, Maingonnat C, Etancelin P, Feuillard J, Bastard C, Tilly H, Jardin F, Ruminy P.

Am J Hematol. 2017 Jan;92(1):68-76. doi: 10.1002/ajh.24584.

35.

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.

Camus V, Stamatoullas A, Mareschal S, Viailly PJ, Sarafan-Vasseur N, Bohers E, Dubois S, Picquenot JM, Ruminy P, Maingonnat C, Bertrand P, Cornic M, Tallon-Simon V, Becker S, Veresezan L, Frebourg T, Vera P, Bastard C, Tilly H, Jardin F.

Haematologica. 2016 Sep;101(9):1094-101. doi: 10.3324/haematol.2016.145102. Epub 2016 Jun 13.

36.

Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response.

Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, Jardin F, Becker S.

Clin Cancer Res. 2016 Jul 1;22(13):3414-5. doi: 10.1158/1078-0432.CCR-16-0783. No abstract available.

37.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K.

Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.

38.

Selecting radiomic features from FDG-PET images for cancer treatment outcome prediction.

Lian C, Ruan S, Denœux T, Jardin F, Vera P.

Med Image Anal. 2016 Aug;32:257-68. doi: 10.1016/j.media.2016.05.007. Epub 2016 May 19.

PMID:
27236221
39.

HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations.

Bouzelfen A, Alcantara M, Kora H, Picquenot JM, Bertrand P, Cornic M, Mareschal S, Bohers E, Maingonnat C, Ruminy P, Adriouch S, Boyer O, Dubois S, Bastard C, Tilly H, Latouche JB, Jardin F.

Leuk Res. 2016 Jun;45:90-100. doi: 10.1016/j.leukres.2016.04.007. Epub 2016 Apr 11.

PMID:
27107267
40.

Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.

Emadali A, Hoghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset FL, Bertrand P, Roumier C, Roggy A, Suchaud-Martin C, Chauvet M, Bertrand S, Hamaidia S, Rousseaux S, Josserand V, Charles J, Templier I, Maeda T, Bruder-Costa J, Chaperot L, Plumas J, Jacob MC, Bonnefoix T, Park S, Gressin R, Tensen CP, Mecucci C, Macintyre E, Leroux D, Brambilla E, Nguyen-Khac F, Luquet I, Penther D, Bastard C, Jardin F, Lefebvre C, Garnache F, Callanan MB.

Blood. 2016 Jun 16;127(24):3040-53. doi: 10.1182/blood-2015-09-671040. Epub 2016 Apr 8.

41.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

42.

Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.

Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, Jardin F, Becker S.

Clin Cancer Res. 2016 Aug 1;22(15):3801-9. doi: 10.1158/1078-0432.CCR-15-2825. Epub 2016 Mar 2.

43.

Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.

Camus V, Sarafan-Vasseur N, Bohers E, Dubois S, Mareschal S, Bertrand P, Viailly PJ, Ruminy P, Maingonnat C, Lemasle E, Stamatoullas A, Picquenot JM, Cornic M, Beaussire L, Bastard C, Frebourg T, Tilly H, Jardin F.

Leuk Lymphoma. 2016 Sep;57(9):2171-9. doi: 10.3109/10428194.2016.1139703. Epub 2016 Feb 17.

PMID:
26883583
44.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F.

Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.

45.

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.

Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, Delfau-Larue MH, Lhermitte L, Thieblemont C, Ribrag V, Cheze S, Sanhes L, Jardin F, Lefrère F, Delarue R, Hoster E, Dreyling M, Asnafi V, Hermine O, Macintyre E.

Haematologica. 2016 Mar;101(3):336-45. doi: 10.3324/haematol.2015.134957. Epub 2015 Dec 24.

46.

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R.

Am J Hematol. 2016 Jun;91(4):366-70. doi: 10.1002/ajh.24278.

47.

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B.

Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X. Epub 2015 Mar 17.

PMID:
26687958
48.

The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.

Dubois S, Jardin F.

Expert Rev Hematol. 2016 Mar;9(3):255-69. doi: 10.1586/17474086.2016.1130616. Epub 2016 Jan 14. Review.

PMID:
26652775
49.

Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.

Mareschal S, Dubois S, Viailly PJ, Bertrand P, Bohers E, Maingonnat C, Jaïs JP, Tesson B, Ruminy P, Peyrouze P, Copie-Bergman C, Fest T, Jo Molina T, Haioun C, Salles G, Tilly H, Lecroq T, Leroy K, Jardin F.

Genes Chromosomes Cancer. 2016 Mar;55(3):251-67. doi: 10.1002/gcc.22328. Epub 2015 Nov 26.

PMID:
26608593
50.

Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.

Chantepie SP, Mear JB, Guittet L, Dervaux B, Marolleau JP, Jardin F, Dutheil JJ, Parienti JJ, Vilque JP, Reman O.

Trials. 2015 Nov 23;16:533. doi: 10.1186/s13063-015-1057-7.

Supplemental Content

Loading ...
Support Center